Possible therapeutic applications of single-chain antibodies in systemic autoimmune diseases

Bibliography

• LESAGE S, GOODNOW CC: Organ-specific autoimmune disease: a deficiency of tolerogenic stimulation. J. Exp. Med. (2001) 194(5):F31-F36.
   PubMed Web of Science ®Google Scholar
• ENZLER T, BONIZZI G, SILVERMAN GJ et al.: Alternative and classical NF-kappa B signaling retain autoreactive B cells in the splenic marginal zone and result in lupus-like disease. Immunity (2006) 25(3):403-415.
   PubMed Web of Science ®Google Scholar
• YOUINOU P, HILLION S, JAMIN C et al.: B lymphocytes on the front line of autoimmunity. Autoimmun. Rev. (2006) 5(3):215-221.
   PubMed Web of Science ®Google Scholar
• DORNER T: Crossroads of B cell activation in autoimmunity: rationale of targeting B cells. J. Rheumatol. Suppl. (2006) 77:3-11.
   PubMedGoogle Scholar
• JOZSI M, PRECHL J, BAJTAY Z, ERDEI A: Complement receptor type 1 (CD35) mediates inhibitory signals in human B lymphocytes. J. Immunol. (2002) 168(6):2782-2788.
   PubMed Web of Science ®Google Scholar
• RABINOVITCH N, GELFAND EW: Expression of functional activating and inhibitory Fcgamma receptors on human B cells. Int. Arch. Allergy Immunol. (2004) 133(3):285-294.
   PubMed Web of Science ®Google Scholar
• BARRINGTON RA, ZHANG M, ZHONG X et al.: CD21/CD19 coreceptor signaling promotes B cell survival during primary immune responses. J. Immunol. (2005) 175(5):2859-2867.
   PubMed Web of Science ®Google Scholar
• BOSSEN C, SCHNEIDER P: BAFF, APRIL and their receptors: structure, function and signaling. Semin. Immunol. (2006) 18(5):263-275.
   PubMed Web of Science ®Google Scholar
• TAYLOR PC, WILLIAMS RO, MAINI RN: Immunotherapy for rheumatoid arthritis. Curr. Opin. Immunol. (2001) 13(5):611-616.
   PubMed Web of Science ®Google Scholar
• KAPLAN M: Eculizumab (Alexion). Curr. Opin. Investig. Drugs (2002) 3(7):1017-1023.
   PubMedGoogle Scholar
• TAYLOR PC: Anti-TNF therapy for rheumatoid arthritis and other inflammatory diseases. Mol. Biotechnol. (2001) 19(2):153-168.
   PubMed Web of Science ®Google Scholar
• FLEISCHMANN RM, SCHECHTMAN J, BENNETT R et al.: Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial. Arthritis Rheum. (2003) 48(4):927-934.
   PubMed Web of Science ®Google Scholar
• HASLER P: Biological therapies directed against cells in autoimmune disease. Springer Semin. Immunopathol. (2006) 27(4):443-456.
   PubMed Web of Science ®Google Scholar
• FELDMANN M, STEINMAN L: Design of effective immunotherapy for human autoimmunity. Nature (2005) 435(7042):612-619.
   PubMed Web of Science ®Google Scholar
• CLARK M: Antibody humanization: a case of the ‘Emperor’s new clothes’? Immunol. Today (2000) 21(8):397-402.
   PubMedGoogle Scholar
• BOULIANNE GL, HOZUMI N, SHULMAN MJ: Production of functional chimaeric mouse/human antibody. Nature (1984) 312(5995):643-646.
   PubMed Web of Science ®Google Scholar
• MORRISON SL, JOHNSON MJ, HERZENBERG LA, OI VT: Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc. Natl. Acad. Sci. USA (1984) 81(21):6851-6855.
   PubMed Web of Science ®Google Scholar
• KUUS-REICHEL K, GRAUER LS, KARAVODIN LM et al.: Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal antibodies? Clin. Diagn. Lab. Immunol. (1994) 1(4):365-372.
   PubMedGoogle Scholar
• WINTER G, GRIFFITHS AD, HAWKINS RE, HOOGENBOOM HR: Making antibodies by phage display technology. Annu. Rev. Immunol. (1994) 12:433-455.
   PubMed Web of Science ®Google Scholar
• LOW NM, HOLLIGER PH, WINTER G: Mimicking somatic hypermutation: affinity maturation of antibodies displayed on bacteriophage using a bacterial mutator strain. J. Mol. Biol. (1996) 260(3):359-368.
   PubMed Web of Science ®Google Scholar
• BRUGGEMANN M, SPICER C, BULUWELA L et al.: Human antibody production in transgenic mice: expression from 100 kb of the human IgH locus. Eur. J. Immunol. (1991) 21(5):1323-1326.
   PubMed Web of Science ®Google Scholar
• MENDEZ MJ, GREEN LL, CORVALAN JR et al.: Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. Nat. Genet. (1997) 15(2):146-156.
   PubMed Web of Science ®Google Scholar
• BENJAMIN RJ, COBBOLD SP, CLARK MR, WALDMANN H: Tolerance to rat monoclonal antibodies. Implications for serotherapy. J. Exp. Med. (1986) 163(6):1539-1552.
   PubMed Web of Science ®Google Scholar
• SUNTHARALINGAM G, PERRY MR, WARD S et al.: Cytokine storm in a Phase I trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. (2006) 355(10):1018-1028.
   PubMed Web of Science ®Google Scholar
• KLEINSCHMIDT-DEMASTERS BK, TYLER KL: Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N. Engl. J. Med. (2005) 353(4):369-374.
   PubMed Web of Science ®Google Scholar
• LANGER-GOULD A, ATLAS SW, GREEN AJ, BOLLEN AW, PELLETIER D: Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N. Engl. J. Med. (2005) 353(4):375-381.
   PubMed Web of Science ®Google Scholar
• VAN ASSCHE G, VAN RANST M, SCIOT R et al.: Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N. Engl. J. Med. (2005) 353(4):362-368.
   PubMed Web of Science ®Google Scholar
• WEAVER AL: Efficacy and safety of the anti-TNF biologic agents. Mod. Rheumatol. (2004) 14(2):101-112.
   PubMedGoogle Scholar
• FELDMANN M, MAINI RN: Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu. Rev. Immunol. (2001) 19:163-196.
   PubMed Web of Science ®Google Scholar
• BRESNIHAN B, ALVARO-GRACIA JM, COBBY M et al.: Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. (1998) 41(12):2196-2204.
   PubMed Web of Science ®Google Scholar
• CAMPION GV, LEBSACK ME, LOOKABAUGH J, GORDON G, CATALANO M: Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. The IL-1Ra Arthritis Study Group. Arthritis Rheum. (1996) 39(7):1092-1101.
   PubMed Web of Science ®Google Scholar
• PRESTA LG: Engineering antibodies for therapy. Curr. Pharm. Biotechnol. (2002) 3(3):237-256.
   PubMedGoogle Scholar
• FREDERICKS ZL, FORTE C, CAPUANO IV et al.: Identification of potent human anti-IL-1RI antagonist antibodies. Protein Eng. Des. Sel. (2004) 17(1):95-106.
   PubMed Web of Science ®Google Scholar
• COSTA GL, SANDORA MR, NAKAJIMA A et al.: Adoptive immunotherapy of experimental autoimmune encephalomyelitis via T cell delivery of the IL-12 p40 subunit. J. Immunol. (2001) 167(4):2379-2387.
   PubMed Web of Science ®Google Scholar
• NAKAJIMA A, SEROOGY CM, SANDORA MR et al.: Antigen-specific T cell-mediated gene therapy in collagen-induced arthritis. J. Clin. Invest. (2001) 107(10):1293-1301.
   PubMed Web of Science ®Google Scholar
• FIFE BT, GRIFFIN MD, ABBAS AK, LOCKSLEY RM, BLUESTONE JA: Inhibition of T cell activation and autoimmune diabetes using a B cell surface-linked CTLA-4 agonist. J. Clin. Invest. (2006) 116(8):2252-2261.
   PubMed Web of Science ®Google Scholar
• NAKAJIMA A: Application of cellular gene therapy for rheumatoid arthritis. Mod. Rheumatol. (2006) 16(5):269-275.
   PubMedGoogle Scholar
• DALL’ERA M, DAVIS J: CTLA4Ig: a novel inhibitor of costimulation. Lupus (2004) 13(5):372-376.
   PubMed Web of Science ®Google Scholar
• EHLERS M, FUKUYAMA H, MCGAHA TL, ADEREM A, RAVETCH JV: TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2b autoantibodies in SLE. J. Exp. Med. (2006) 203(3):553-561.
   PubMed Web of Science ®Google Scholar
• CHRISTENSEN SR, SHUPE J, NICKERSON K et al.: Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity (2006) 25(3):417-428.
   PubMed Web of Science ®Google Scholar
• GRAMMER AC, LIPSKY PE: B cell abnormalities in systemic lupus erythematosus. Arthritis Res. Ther. (2003) 5(Suppl. 4):S22-S27.
   PubMed Web of Science ®Google Scholar
• DING C, JONES G: Belimumab Human Genome Sciences/Cambridge Antibody Technology/GlaxoSmithKline. Curr. Opin. Investig. Drugs (2006) 7(5):464-472.
   PubMed Web of Science ®Google Scholar
• COHEN SB: Updates from B cell trials: efficacy. J. Rheumatol. Suppl. (2006) 77:12-17.
   PubMedGoogle Scholar
• ERNST JA, LI H, KIM HS et al.: Isolation and characterization of the B-cell marker CD20. Biochemistry (2005) 44(46):15150-15158.
   PubMed Web of Science ®Google Scholar
• CAMBRIDGE G, LEANDRO MJ, EDWARDS JC et al.: Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum. (2003) 48(8):2146-2154.
   PubMed Web of Science ®Google Scholar
• STOHL W, LOONEY RJ: B cell depletion therapy in systemic rheumatic diseases: different strokes for different folks? Clin. Immunol. (2006) 121(1):1-12.
   PubMed Web of Science ®Google Scholar
• COHEN SB, EMERY P, GREENWALD MW et al.: Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, Phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. (2006) 54(9):2793-2806.
   PubMed Web of Science ®Google Scholar
• ALOISI F, PUJOL-BORRELL R: Lymphoid neogenesis in chronic inflammatory diseases. Nat. Rev. Immunol. (2006) 6(3):205-217.
   PubMed Web of Science ®Google Scholar
• MARTIN F, CHAN AC: Pathogenic roles of B cells in human autoimmunity; insights from the clinic. Immunity (2004) 20(5):517-527.
   PubMed Web of Science ®Google Scholar
• EDWARDS JC, CAMBRIDGE G, LEANDRO MJ: B cell depletion therapy in rheumatic disease. Best Pract. Res. Clin. Rheumatol. (2006) 20(5):915-928.
   PubMed Web of Science ®Google Scholar
• DORNER T, KAUFMANN J, WEGENER WA et al.: Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res. Ther. (2006) 8(3):R74.
   PubMed Web of Science ®Google Scholar
• CARNAHAN J, WANG P, KENDALL R et al.: Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clin. Cancer Res. (2003) 9(10 Pt 2):3982S-3990S.
   PubMed Web of Science ®Google Scholar
• NIMMERJAHN F, RAVETCH JV: Fcgamma receptors: old friends and new family members. Immunity (2006) 24(1):19-28.
   PubMed Web of Science ®Google Scholar
• SOLOMON S, KASSAHN D, ILLGES H: The role of the complement and the Fc gamma R system in the pathogenesis of arthritis. Arthritis Res. Ther. (2005) 7(4):129-135.
   PubMed Web of Science ®Google Scholar
• STEWART-AKERS AM, CUNNINGHAM A, WASKO MC, MOREL PA: Fc gamma R expression on NK cells influences disease severity in rheumatoid arthritis. Genes Immun. (2004) 5(7):521-529.
   PubMed Web of Science ®Google Scholar
• NIGROVIC PA, LEE DM: Mast cells in inflammatory arthritis. Arthritis Res. Ther. (2005) 7(1):1-11.
   PubMed Web of Science ®Google Scholar
• GERARD C, GERARD NP: C5A anaphylatoxin and its seven transmembrane-segment receptor. Annu. Rev. Immunol. (1994) 12:775-808.
   PubMed Web of Science ®Google Scholar
• ISAAK A, PRECHL J, GERGELY J, ERDEI A: The role of CR2 in autoimmunity. Autoimmunity (2006) 39(5):357-366.
   PubMed Web of Science ®Google Scholar
• DREJA H, ANNENKOV A, CHERNAJOVSKY Y: Soluble complement receptor 1(CD35) delivered by retrovirally infected syngeneic cells or by naked DNA injection prevents the progression of collagen-induced arthritis. Arthritis Rheum. (2000) 43(8):1698-1709.
   PubMed Web of Science ®Google Scholar
• WHISS PA: Pexelizumab Alexion. Curr. Opin. Investig. Drugs (2002) 3(6):870-877.
   PubMedGoogle Scholar
• KORGANOW AS, JI H, MANGIALAIO S et al.: From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. Immunity (1999) 10(4):451-461.
   PubMed Web of Science ®Google Scholar
• KYBURZ D, CORR M: The KRN mouse model of inflammatory arthritis. Springer Semin. Immunopathol. (2003) 25(1):79-90.
   PubMed Web of Science ®Google Scholar
• TAKAI T: Roles of Fc receptors in autoimmunity. Nat. Rev. Immunol. (2002) 2(8):580-592.
   PubMed Web of Science ®Google Scholar
• TAKAI T: Fc receptors and their role in immune regulation and autoimmunity. J. Clin. Immunol. (2005) 25(1):1-18.
   PubMed Web of Science ®Google Scholar
• TSUCHIYA N, KYOGOKU C: Role of Fc gamma receptor IIb polymorphism in the genetic background of systemic lupus erythematosus: insights from Asia. Autoimmunity (2005) 38(5):347-352.
   PubMed Web of Science ®Google Scholar
• SIRIBOONRIT U, TSUCHIYA N, SIRIKONG M et al.: Association of Fcgamma receptor IIb and IIIb polymorphisms with susceptibility to systemic lupus erythematosus in Thais. Tissue Antigens (2003) 61(5):374-383.
   PubMed Web of Science ®Google Scholar
• KONO H, KYOGOKU C, SUZUKI T et al.: FcgammaRIIB Ile232Thr transmembrane polymorphism associated with human systemic lupus erythematosus decreases affinity to lipid rafts and attenuates inhibitory effects on B cell receptor signaling. Hum. Mol. Genet. (2005) 14(19):2881-2892.
   PubMed Web of Science ®Google Scholar
• MACKAY M, STANEVSKY A, WANG T et al.: Selective dysregulation of the FcgammaIIB receptor on memory B cells in SLE. J. Exp. Med. (2006) 203(9):2157-2164.
   PubMed Web of Science ®Google Scholar
• GAULD SB, MERRELL KT, CAMBIER JC: Silencing of autoreactive B cells by anergy: a fresh perspective. Curr. Opin. Immunol. (2006) 18(3):292-297.
   PubMed Web of Science ®Google Scholar
• RANKIN CT, VERI MC, GORLATOV S et al.: CD32B, the human inhibitory Fc-gamma receptor IIB, as a target for monoclonal antibody therapy of B-cell lymphoma. Blood (2006) 108(7):2384-2391.
   PubMed Web of Science ®Google Scholar
• SULICA A, MOREL P, METES D, HERBERMAN RB: Ig-binding receptors on human NK cells as effector and regulatory surface molecules. Int. Rev. Immunol. (2001) 20(3-4):371-414.
   PubMedGoogle Scholar
• BORUCHOV AM, HELLER G, VERI MC et al.: Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. J. Clin. Invest. (2005) 115(10):2914-2923.
   PubMed Web of Science ®Google Scholar
• KOHLER G, MILSTEIN C: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature (1975) 256(5517):495-497.
   PubMed Web of Science ®Google Scholar
• BIRD RE, HARDMAN KD, JACOBSON JW et al.: Single-chain antigen-binding proteins. Science (1988) 242(4877):423-426.
   PubMed Web of Science ®Google Scholar
• KIM SJ, PARK Y, HONG HJ: Antibody engineering for the development of therapeutic antibodies. Mol. Cells (2005) 20(1):17-29.
   PubMed Web of Science ®Google Scholar
• CHAPMAN AP: PEGylated antibodies and antibody fragments for improved therapy: a review. Adv. Drug Deliv. Rev. (2002) 54(4):531-545.
   PubMed Web of Science ®Google Scholar
• CHOWDHURY PS, PASTAN I: Improving antibody affinity by mimicking somatic hypermutation in vitro. Nat. Biotechnol. (1999) 17(6):568-572.
   PubMed Web of Science ®Google Scholar
• LIPOVSEK D, PLUCKTHUN A: In vitro protein evolution by ribosome display and mRNA display. J. Immunol. Methods (2004) 290(1-2):51-67.
   PubMed Web of Science ®Google Scholar
• JERMUTUS L, HONEGGER A, SCHWESINGER F, HANES J, PLUCKTHUN A: Tailoring in vitro evolution for protein affinity or stability. Proc. Natl. Acad. Sci. USA (2001) 98(1):75-80.
   PubMed Web of Science ®Google Scholar
• CHAPMAN AP, ANTONIW P, SPITALI M et al.: Therapeutic antibody fragments with prolonged in vivo half-lives. Nat. Biotechnol. (1999) 17(8):780-783.
   PubMed Web of Science ®Google Scholar
• CHOWDHURY PS: Engineering hot spots for affinity enhancement of antibodies. Methods Mol. Biol. (2003) 207:179-196.
   PubMedGoogle Scholar
• GEORGIOU G, STATHOPOULOS C, DAUGHERTY PS et al.: Display of heterologous proteins on the surface of microorganisms: from the screening of combinatorial libraries to live recombinant vaccines. Nat. Biotechnol. (1997) 15(1):29-34.
   PubMed Web of Science ®Google Scholar
• FRANCISCO JA, CAMPBELL R, IVERSON BL, GEORGIOU G: Production and fluorescence-activated cell sorting of Escherichia coli expressing a functional antibody fragment on the external surface. Proc. Natl. Acad. Sci. USA (1993) 90(22):10444-10448.
   PubMed Web of Science ®Google Scholar
• HANES J, PLUCKTHUN A: In vitro selection and evolution of functional proteins by using ribosome display. Proc. Natl. Acad. Sci. USA (1997) 94(10):4937-4942.
   PubMed Web of Science ®Google Scholar
• CORBEL SY, ROSSI FM: Latest developments and in vivo use of the Tet system: ex vivo and in vivo delivery of tetracycline-regulated genes. Curr. Opin. Biotechnol. (2002) 13(5):448-452.
   PubMed Web of Science ®Google Scholar
• VAN DER KRAAN PM, VAN DE LOO FA, VAN DEN BERG WB: Role of gene therapy in tissue engineering procedures in rheumatology: the use of animal models. Biomaterials (2004) 25(9):1497-1504.
   PubMed Web of Science ®Google Scholar
• VAN DE LOO FA, SMEETS RL, VAN DEN BERG WB: Gene therapy in animal models of rheumatoid arthritis: are we ready for the patients? Arthritis Res. Ther. (2004) 6(5):183-196.
   PubMed Web of Science ®Google Scholar
• SMITH R, TARNER IH, HOLLENHORST M et al.: Localized expression of an anti-TNF single-chain antibody prevents development of collagen-induced arthritis. Gene Ther. (2003) 10(15):1248-1257.
   PubMed Web of Science ®Google Scholar
• TARNER IH, NAKAJIMA A, SEROOGY CM et al.: Retroviral gene therapy of collagen-induced arthritis by local delivery of IL-4. Clin. Immunol. (2002) 105(3):304-314.
   PubMed Web of Science ®Google Scholar
• TARNER IH, SLAVIN AJ, MCBRIDE J et al.: Treatment of autoimmune disease by adoptive cellular gene therapy. Ann. NY Acad. Sci. (2003) 998:512-519.
   PubMed Web of Science ®Google Scholar
• TARNER IH, FATHMAN CG: The potential for gene therapy in the treatment of autoimmune disease. Clin. Immunol. (2002) 104(3):204-216.
   PubMed Web of Science ®Google Scholar
• REYNOLDS P, DMITRIEV I, CURIEL D: Insertion of an RGD motif into the HI loop of adenovirus fiber protein alters the distribution of transgene expression of the systemically administered vector. Gene Ther. (1999) 6(7):1336-1339.
   PubMed Web of Science ®Google Scholar
• BAKKER AC, VAN DE LOO FA, JOOSTEN LA et al.: A tropism-modified adenoviral vector increased the effectiveness of gene therapy for arthritis. Gene Ther. (2001) 8(23):1785-1793.
   PubMed Web of Science ®Google Scholar
• MOORE PA, BELVEDERE O, ORR A et al.: BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science (1999) 285(5425):260-263.
   PubMed Web of Science ®Google Scholar
• SCHNEIDER P, MACKAY F, STEINER V et al.: BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J. Exp. Med. (1999) 189(11):1747-1756.
   PubMed Web of Science ®Google Scholar
• YAN M, MARSTERS SA, GREWAL IS et al.: Identification of a receptor for BLyS demonstrates a crucial role in humoral immunity. Nat. Immunol. (2000) 1(1):37-41.
   PubMed Web of Science ®Google Scholar
• ZHANG J, ROSCHKE V, BAKER KP et al.: Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J. Immunol. (2001) 166(1):6-10.
   PubMed Web of Science ®Google Scholar
• ROLINK AG, MELCHERS F: BAFFled B cells survive and thrive: roles of BAFF in B-cell development. Curr. Opin. Immunol. (2002) 14(2):266-275.
   PubMed Web of Science ®Google Scholar
• ROLINK AG, TSCHOPP J, SCHNEIDER P, MELCHERS F: BAFF is a survival and maturation factor for mouse B cells. Eur. J. Immunol. (2002) 32(7):2004-2010.
   PubMed Web of Science ®Google Scholar
• MELCHERS F: Actions of BAFF in B cell maturation and its effects on the development of autoimmune disease. Ann. Rheum. Dis. (2003) 62(Suppl. 2):ii25-ii27.
   PubMedGoogle Scholar
• WANG H, MARSTERS SA, BAKER T et al.: TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice. Nat. Immunol. (2001) 2(7):632-637.
   PubMed Web of Science ®Google Scholar
• KAYAGAKI N, YAN M, SESHASAYEE D et al.: BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2. Immunity (2002) 17(4):515-524.
   PubMed Web of Science ®Google Scholar
• BAKER KP, EDWARDS BM, MAIN SH et al.: Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum. (2003) 48(11):3253-3265.
   PubMed Web of Science ®Google Scholar
• CAO P, XIA Z, SONG W, ZHANG S: Neutralizing human anti-B-cell-activating factor of the TNF family (BAFF) scFv selected from phage antibody library. Immunol. Lett. (2005) 101(1):87-94.
   PubMed Web of Science ®Google Scholar
• LIU MY, HAN W, DING YL et al.: Generation and characterization of C305, a murine neutralizing scFv antibody that can inhibit BLyS binding to its receptor BCMA. Acta Biochim. Biophys. Sin. (Shanghai) (2005) 37(6):415-420.
   Google Scholar
• LENSCHOW DJ, WALUNAS TL, BLUESTONE JA: CD28/B7 system of T cell costimulation. Annu. Rev. Immunol. (1996) 14:233-258.
   PubMed Web of Science ®Google Scholar
• SUN Y, LIN X, CHEN HM et al.: Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of experimental autoimmune encephalomyelitis. J. Immunol. (2002) 168(3):1457-1465.
   PubMed Web of Science ®Google Scholar
• SUN Y, CHEN HM, SUBUDHI SK et al.: Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease. Nat. Med. (2002) 8(12):1405-1413.
   PubMed Web of Science ®Google Scholar
• LEE UH, SON JH, LEE JJ et al.: Humanization of antagonistic anti-human 4-1BB monoclonal antibody using a phage-displayed combinatorial library. J. Immunother. (2004) 27(3):201-210.
   PubMed Web of Science ®Google Scholar
• SYTWU HK, LIN WD, ROFFLER SR et al.: Anti-4-1BB-based immunotherapy for autoimmune diabetes: lessons from a transgenic non-obese diabetic (NOD) model. J. Autoimmun. (2003) 21(3):247-254.
   PubMed Web of Science ®Google Scholar
• TOUBI E, SHOENFELD Y: The role of CD40-CD154 interactions in autoimmunity and the benefit of disrupting this pathway. Autoimmunity (2004) 37(6-7):457-464.
   PubMed Web of Science ®Google Scholar
• HOWARD LM, MILLER SD: Immunotherapy targeting the CD40/CD154 costimulatory pathway for treatment of autoimmune disease. Autoimmunity (2004) 37(5):411-418.
   PubMed Web of Science ®Google Scholar
• HOWARD LM, DAL CANTO MC, MILLER SD: Transient anti-CD154-mediated immunotherapy of ongoing relapsing experimental autoimmune encephalomyelitis induces long-term inhibition of disease relapses. J. Neuroimmunol. (2002) 129(1-2):58-65.
   PubMed Web of Science ®Google Scholar
• HOWARD LM, MIGA AJ, VANDERLUGT CL et al.: Mechanisms of immunotherapeutic intervention by anti-CD40L (CD154) antibody in an animal model of multiple sclerosis. J. Clin. Invest. (1999) 103(2):281-290.
   PubMed Web of Science ®Google Scholar
• ELLMARK P, OTTOSSON C, BORREBAECK CA, MALMBORG HAGER AC, FUREBRING C: Modulation of the CD40-CD40 ligand interaction using human anti-CD40 single-chain antibody fragments obtained from the n-CoDeR phage display library. Immunology (2002) 106(4):456-463.
   PubMed Web of Science ®Google Scholar
• GEJIMA R, TANAKA K, NAKASHIMA T et al.: Human single-chain Fv (scFv) antibody specific to human IL-6 with the inhibitory activity on IL-6-signaling. Hum. Antibodies (2002) 11(4):121-129.
   Web of Science ®Google Scholar
• SIMS JE: IL-1 and IL-18 receptors, and their extended family. Curr. Opin. Immunol. (2002) 14(1):117-122.
   PubMed Web of Science ®Google Scholar
• HAMASAKI T, HASHIGUCHI S, ITO Y et al.: Human anti-human IL-18 antibody recognizing the IL-18-binding site 3 with IL-18 signaling blocking activity. J. Biochem. (Tokyo) (2005) 138(4):433-442.
   PubMed Web of Science ®Google Scholar
• GRIFFIN MD, HONG DK, HOLMAN PO et al.: Blockade of T cell activation using a surface-linked single-chain antibody to CTLA-4 (CD152). J. Immunol. (2000) 164(9):4433-4442.
   PubMed Web of Science ®Google Scholar
• JANAS E, PRIEST R, WILDE JI, WHITE JH, MALHOTRA R: Rituxan (anti-CD20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis. Clin. Exp. Immunol. (2005) 139(3):439-446.
   PubMed Web of Science ®Google Scholar
• HOLLIGER P, HUDSON PJ: Engineered antibody fragments and the rise of single domains. Nat. Biotechnol. (2005) 23(9):1126-1136.
   PubMed Web of Science ®Google Scholar
• KURUCZ I, TITUS JA, JOST CR, SEGAL DM: Correct disulfide pairing and efficient refolding of detergent-solubilized single-chain Fv proteins from bacterial inclusion bodies. Mol. Immunol. (1995) 32(17-18):1443-1452.
   PubMed Web of Science ®Google Scholar
• KURUCZ I, HILBERT A, KAPUS A et al.: Bacterially expressed human Fc gamma RIIb is soluble and functionally active after in vitro refolding. Immunol. Lett. (2000) 75(1):33-40.
   PubMed Web of Science ®Google Scholar
• MOGHIMI SM, HUNTER AC, MURRAY JC: Nanomedicine: current status and future prospects. FASEB J. (2005) 19(3):311-330.
   PubMed Web of Science ®Google Scholar
• ADRIAANSEN J, VERVOORDELDONK MJ, TAK PP: Gene therapy as a therapeutic approach for the treatment of rheumatoid arthritis: innovative vectors and therapeutic genes. Rheumatology (Oxford) (2006) 45(6):656-668.
   PubMed Web of Science ®Google Scholar
• CAO P, TANG XM, GUAN ZB, DIAO ZY, ZHANG SQ: Production and characterization of a bacterial single-chain antibody fragment specific to B-cell-activating factor of the TNF family. Protein Expr. Purif. (2005) 43(2):157-164.
   Google Scholar
• ANNENKOV A, CHERNAJOVSKY Y: Engineering mouse T lymphocytes specific to type II collagen by transduction with a chimeric receptor consisting of a single chain Fv and TCR zeta. Gene Ther. (2000) 7(8):714-722.
   Google Scholar
• BLANK M, WAISMAN A, MOZES E, KOIKE T, SHOENFELD Y: Characteristics and pathogenic role of anti-beta2-glycoprotein I single-chain Fv domains: induction of experimental antiphospholipid syndrome. Int. Immunol. (1999) 11(12):1917-1926.
   PubMed Web of Science ®Google Scholar